Resistance of ER-positive breast cancer to tamoxifen therapy may be driven by APOBEC3
Responses to tamoxifen were significantly prolonged by reducing levels of the enzyme APOBEC3B in preclinical models of estrogen receptor-positive breast cancer and significantly shortened by...